https://orcid.org/0000-0002-3290-1909
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Objectives
This retrospective cohort study assessed the clinical effectiveness of nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis(LC).
Methods
The data of non-hospitalized adult patients with LC who had COVID-19 were selected from the TriNetX platform for the period between 1 March 20201 March 2020, and 31 December 202231 December 2022. Propensity score matching was used to match patients receiving NMV-r (theNMV-r group) with those not receiving NMV-r (the control group). Hazard ratios(HRs) along with 95% confidence intervals (CIs) for the primary outcome – a composite of all-cause hospitalization or mortality during the 30-day follow-up period – were calculated and compared.
Results
Two cohorts of 2,369 patients each with balanced baseline characteristics were identified.During the follow-up period, the NMV-r group had a lower risk of all-cause hospitalization or mortality (HR, 0.642;95% CI, 0.503–0.819) than did the control group.NMV-r was also associated with a reduced risk of individual all-cause hospitalization (HR 0.681, 95% CI 0.530–0.876])and all-cause mortality (HR, 0.270; 95% CI,0.129–0.562). This association was consistently observed in the subgroups of age, sex, vaccination status, and LC severity.
Conclusions
NMV-r can reduce all-cause hospitalization and mortality among patients with LC who have COVID-19.
Abbreviations
| CLD | = | chronic liver disease |
| COVID-19 | = | coronavirus disease 2019 |
| HCO | = | health-care organization |
| NMV-r | = | nirmatrelvir plus ritonavir |
| LC | = | liver cirrhosis |
| SARS-CoV-2 | = | severe acute respiratory syndrome coronavirus 2 |
Declaration of interest
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contribution statement
The authors have substantially contributed to the conception and design of this article as well as the interpretation of relevant literature. In addition, the authors have been involved in writing the article and revising it for intellectual content.
Supplementary material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/14787210.2023.2267846.